

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

C177
PATENT & TRADEMARK OFFICE
AUG 06 2001

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

RECEIVED
TECH CENTER 600/2900
AUG 08 2001

Complete if Known						
				Application Number		09/825,925
				Filing Date		05 April 2001
				First Named Inventor		Samuel RAHBAR
				Group Art Unit		1614
Examiner Name				Not Yet Assigned		
Sheet	2	of	5	Attorney Docket Number	1954-373	
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
VJ		Al-Abed, Y. et al. "Inhibition of advanced glycation endproduct formation by acetaldehyde: Role in the cardioprotective effect of ethanol", <i>Proc. Natl. Acad. Sci. USA</i> , Mar. 1999; 96:2385-2390				
VM		Asif, M. et al. "An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness", <i>PNAS</i> , Mar. 14, 2000; 97(6):2809-2813				
VM		Boel, E. et al. "Diabetic Late Complications: Will Aldose Reductase Inhibitors or Inhibitors of Advanced Glycosylation Endproduct Formation Hold Promise?", <i>J. Diabetes and Its Complications</i> , 1995; 9:104-129				
VM		Booth, A.A. et al. "Thiamine Pyrophosphate and Pyridoxamine Inhibit the Formation of Antigenic Advanced Glycation End-Products: Comparison with Aminoguanidine", <i>Biochem. Biophys. Res. Commun.</i> , 1996; 220:113-119				
VM		Booth, A.A. et al. "In Vitro Kinetic Studies of Formation of Antigenic Advanced Glycation End Products (AGEs)", <i>Journal of Biological Chemistry</i> , Feb. 28, 1997; 272(9):5430-5437				
VM		Calatayud J.J., "Favorable Effects of the Lipid-Lowering and Platelet Antiaggregant Plafibrilde on the Aging Process of Mice of the C57BL/6J Strain," <i>Math and Find Exptl Clin Pharmacol</i> , 1983; 5(10):707-714				
VM	✓	Cameron, N.E. et al. "Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats", <i>Diabetologia</i> ; 1992; 35:946-950				
VM	✓	Corbett, J.A. et al. "Aminoguanidine, a Novel Inhibitor of Nitric Oxide Formation, Prevents Diabetic Vascular Dysfunction", <i>Diabetes</i> , April 1992; 41:552-556				
VM	✓	Cooper, M.E. et al., "The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation," <i>Diabetologia</i> , 2000; 43:660-664				
VM	✓	Durany, N. et al. "Investigations on oxidative stress and therapeutical implications in dementia", <i>Eur. Arch. Psychiatry Clin. Neurosci.</i> , 1999; 249:Suppl. 3 III/68-III/73				
VM	✓	Hirsch, J. et al., "The reaction of some dicarbonyl sugars with aminoguanidine," <i>Carbohydrate Research</i> , 1992; 232:125-130				
VM	✓	Jakus, V. et al. "Inhibition of Nonenzymatic Protein Glycation and Lipid Peroxidation by Drugs with Antioxidant Activity", <i>Life Sciences</i> , 1999; 65(18-19):1991-1993				
Examiner Signature	<i>V. Balasubramanian</i>			Date Considered	6/28/02	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

AUG 06 2001
USPTO
PATENT & TRADEMARK OFFICE
PTO-177

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

TECH CENTER 1600/2000

AUG 08 2001

RECEIVED

				Complete if Known	
				Application Number	09/825,925
				Filing Date	05 April 2001
				First Named Inventor	Samuel RAHBAR
				Group Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	3	of	5	Attorney Docket Number	1954-373

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
VB	/	Jyothirmayi, G.N. et al. "Effects of Metformin on Collagen Glycation and Diastolic Dysfunction in Diabetic Myocardium", <i>J. Cardiovasc. Pharmacol. Therapeut.</i> , 1998; 3(4):319-326	
M	/	Khalifah, R.G. "Amadorins: Novel Post-Amadori Inhibitors of Advanced Glycation Reactions", <i>Biochem. Biophys. Res. Commun.</i> , 1999; 257:251-258	
M	/	Kochakian, M. et al. "Chronic Dosing with Aminoguanidine and Novel Advanced Glycosylation End Product-Formation Inhibitors Ameliorates Cross-Linking of Tail Tendon Collagen and STZ-Induced Diabetic Rats", <i>Diabetes</i> , Dec. 1996; 45:1694-1700	
M	/	Malik, N.S. and Meek, K.M. "The Inhibition of Sugar-Induced Structural Alterations in Collagen by Aspirin and Other Compounds", <i>Biochem. Biophys. Res. Commun.</i> , 1994; 199(2):683-686	
B	/	Marques, C. et al. "Bendazac decreases <i>in vitro</i> glycation of human lens crystallins. Decrease of <i>in vitro</i> protein glycation by bendazac", <i>Documenta Ophthalmologica</i> , 1995; 90:395-404	
M	/	Menzel, E.J. et al. "Comparison of the effect of different inhibitors on the non-enzymatic glycation of rat tail tendons and bovine serum albumin", <i>Ann. Clin. Biochem.</i> , 1996; 33:241-248	
M	/	Miwa, I. et al. "Inhibition of Advanced Protein Glycation by 8-Quinolinecarboxylic Hydrazide", <i>Pharmacology</i> , 1996; 52:314-320	
M	/	Morimitsu, Y. et al. "Protein Glycation Inhibitors from Thyme (<i>Thymus vulgaris</i>)", <i>Biosci. Biotech. Biochem.</i> , 1995; 59(11):2018-2021	
M	/	Münch, G. et al. "Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of β-amyloid peptide", <i>Biochimica et Biophysica Acta</i> , 1997; 1360:17-29	
M	/	Münch, G. et al. "Advanced glycation endproducts in ageing and Alzheimer's disease", <i>Brain Research Reviews</i> , 1997; 23:134-143	
M	/	Nakamura, S. et al. "Progression of Nephropathy in Spontaneous Diabetic Rats is Prevented by OPB-9195, a Novel Inhibitor of Advanced Glycation", <i>Diabetes</i> , May 1997; 46:895-899	
M	/	Rahbar, S. and Nadler, J.L. "A new rapid method to detect inhibition of Amadori product generated by δ-gluconolactone", <i>Clinica Chimica Acta</i> , 1999; 287:123-130	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

O
AUG 06 2001
PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE
TECH CENTER 1600/2900
RECEIVED

Complete if Known

Application Number	09/825,925
Filing Date	05 April 2001
First Named Inventor	Samuel RAHBAR
Group Art Unit	1614
Examiner Name	Not Yet Assigned

AUG 08 2001
1600/2900

Sheet 4 of 5 Attorney Docket Number 1954-373

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
W		Rahbar, S. et al. "Novel Inhibitors of Advanced Glycation Endproducts", <i>Biochem. Biophys. Res. Commun.</i> , 1999; 262:651-656	
M		Raj D.S.C., et al., "Advanced Glycation End Products: A Nephrologist's Perspective," <i>American Journal of Kidney Diseases</i> , March 2000; 35(3):365-380	
M		Ruggiero-Lopez, D. et al. "Reaction of Metformin with Dicarbonyl Compounds. Possible Implication in the Inhibition of Advanced Glycation End Product Formation", <i>Biochem. Pharmacology</i> , 1999; 58:1765-1773	
M		Ryan, M.E. et al. "Tetracyclines Inhibit Protein Glycation in Experimental Diabetes", <i>Adv. Dent. Res.</i> , Nov. 1998; 12:152-158	
D		Sensi, M. et al. "D-Lysine reduces the non-enzymatic glycation of proteins in experimental diabetes mellitus in rats", <i>Diabetologia</i> , 1993; 36:797-801	
M		Soulis, T. et al. "Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats", <i>Diabetologia</i> , 1997; 40:1141-1151	
M		Soulis, T. et al. "A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes", <i>Diabetologia</i> 1999; 42:472-479	
V		Swamy-Mruthinti, S. et al. "Acetyl-L-Carnitine Decreases Glycation of Lens Proteins: in vitro Studies", <i>Exp. Eye Res.</i> , 1999; 69:109-115	
V		Taguchi, T. et al. "Inhibition of advanced protein glycation by a Schiff base between aminoguanidine and pyridoxal", <i>European Journal of Pharmacology</i> , 1999; 378:283-289	
V		Tanaka, Y. et al. "Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats", <i>European Journal of Pharmacology</i> , 1999; 376:17-22	
V		Thornalley, P.J. et al., "Rapid Hydrolysis and Slow α , β -Dicarbonyl Cleavage of an Agent Proposed to Cleave Glucose-Derived Protein Cross-Links," <i>Biochemical Pharmacology</i> , 1999; 57:303-307.	
V		Tilton, R.G. et al. "Prevention of Diabetic Vascular Dysfunction by Guanidines. Inhibition of Nitric Oxide Synthase Versus Advanced Glycation End-Product Formation", <i>Diabetes</i> , Feb. 1993; 42:221-232	

Examiner Signature

V. Balasubramanian

Date Considered

6/28/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: right;">AUG 06 2001 PATENT AND TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE</p>				Complete if Known					
				Application Number		09/825,925			
				Filing Date		05 April 2001			
				First Named Inventor		Samuel RAHBAR			
				Group Art Unit		1614			
				Examiner Name		Not Yet Assigned			
Sheet	5	of	5	Attorney Docket Number				1054-373	
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						T ²	
VJ		Tsuchida, K. et al. "Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195", <i>Diabetologia</i> , 1999; 42:579-588							
VJ		Ulrich, P. and Zhang, X. "Pharmacological reversal of advanced glycation end-product-mediated protein crosslinking", <i>Diabetologia</i> , 1997; 40:S157-S159							
VJ		van Boekel, M. et al., "Glycation of human serum albumin: inhibition by Diclofenac", <i>Biochimica et Biophysica Acta</i> , 1992; 1120:201-204							
VJ		Vasan, S. et al. "An agent cleaving glucose-derived protein crosslinks <i>in vitro</i> and <i>in vivo</i> ", <i>Nature</i> , July 18, 1996; 382:275-278							
VJ	<	Wolffenbuttel, B. et al. "Breakers of advanced glycation end products restore large artery properties in experimental diabetes", <i>Proc. Natl. Acad. Sci. USA</i> , April 1998; 95:4630-4634							
Examiner Signature	V. Balasubramanian				Date Considered	6/28/02			

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.